STAT5 Aptamer Inhibitor for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for leukaemias and myeloproliferative neoplasms, such as radiation and chemotherapy, are non-specific and cause significant side effects, while existing inhibitors like Imatinib mesylate and AZD1480 have limitations, including resistance and side effects, highlighting the need for more targeted and specific therapies.
Innovation Solution
Development of specific nucleic acid aptamers that bind to STAT5 protein, inhibiting its activity downstream in the signalling pathway to prevent undesirable side effects, with high specificity and minimal immunogenicity, demonstrating effective anti-proliferative and pro-apoptotic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation or chemotherapy is used to treat leukaemias and myeloproliferative neoplasms, then cancer cell growth is inhibited, but significant side effects occur due to non-specific treatment
Solution Approach 1:
The patent uses STAT5 protein as an intermediary target in the signalling pathway. Instead of directly attacking cancer cells with non-specific radiation or chemotherapy, the aptamer binds to STAT5 protein, which mediates the transmission of signals necessary for cancer cell proliferation. This intermediary approach provides specificity while maintaining treatment effectiveness.
Solution Approach 2:
The patent extracts and targets the specific STAT5 protein component from the complex cancer cell machinery. By isolating this specific protein target and designing aptamers that bind exclusively to it, the treatment can inhibit cancer cell growth without affecting other normal cellular processes, thereby reducing side effects.
2Reliability
If Imatinib mesylate is used as a pharmacological inhibitor, then cancer treatment is achieved, but resistance develops and side effects occur
Solution Approach 1:
The patent replaces the small molecule pharmacological inhibitor (Imatinib mesylate) with a nucleic acid-based aptamer. This substitution changes the mechanism of action from chemical inhibition to specific nucleic acid-protein binding, which may overcome resistance mechanisms that have developed against traditional pharmacological inhibitors.
Solution Approach 2:
The patent changes the fundamental parameter of the inhibitor from a small molecule drug to a nucleic acid aptamer. This parameter change allows for different binding characteristics, stability, and specificity, potentially overcoming resistance that has developed against existing pharmacological inhibitors while maintaining treatment effectiveness.
3Reliability
If STAT5 protein expression is globally inhibited, then cancer cell proliferation is prevented, but undesirable side effects occur due to involvement in various physiological processes
Solution Approach 1:
The patent applies local quality by designing aptamers with high specificity for the activated form of STAT5 protein (phospho-STAT5). This localized inhibition targets only the pathological activated form involved in cancer proliferation, while leaving other forms and functions of STAT5 protein unaffected, thereby preventing side effects associated with global inhibition.
Solution Approach 2:
The patent uses partial action by targeting specifically the activated phosphorylated form of STAT5 protein rather than inhibiting all STAT5 protein activity. This partial inhibition is sufficient to block cancer cell proliferation driven by activated STAT5, while preserving normal physiological functions that depend on unphosphorylated or differently regulated STAT5 activity.
Data Source
AI summary
Provided is a composition of matter binding specifically to STAT5, preferably to STAT5B, including a nucleic acid aptamer, and methods of treatment of cancer, and in particular leukaemia via the inhibition of STAT5 protein. The present invention relates more particularly to specific aptamers of STAT5 protein, and the therapeutic or diagnostic use thereof. Also provided is a method for detecting STAT5 in a biological sample, including contacting a nucleic acid aptamer binding specifically to STAT5 with a sample taken beforehand from a subject and determining the quantity of said aptamer bound to said sample.